Chenpon, founded in 2002, is a comprehensive pharmaceutical company that is engaged in the development, production, distribution and sales of pharmaceuticals. Currently, Chenpon has two manufacturing sites and also cooperates with Shanghai Pharma and Fosun Pharma to manufacture and market drug products. Products of Chenpon cover oral solid dosage and injection, etc., several of which have been approved for “Generic consistency evaluation” in China and one injectable product has been approved by the European Union.
Chenpon has a 1200 m2 modern R&D center in Zhangjiang, Shanghai, China. The R&D team is led by a chief scientist with over 20 years successful inhalation drug development and management experience in United States. Chenpon also maintains long-term cooperation with research institutes, such as Fudan University, Shanghai Jiaotong University, and Shanghai Institute of Materia Medica.
At present, the company's R&D center has established an inhalation research platform to develop a series of inhalation products, covering aerosol and dry powder inhalers. The center is well equipped with inhalation R&D equipment and has a GMP pilot workshop. The ongoing projects include both generic and 505 (b) (2) drug products, in which, several have entered the clinical or submission stage. The company is committed to becoming a leader in the inhalation field.
In the next five years, Chenpon is planning to have 10+ products approved in China, Europe and US, covering injection, oral formulations and Inhalations. Continuously strives for innovation to provide World class products for World Wide Health Care.
